TNF blockers are highly efficacious at dampening inflammation and reducing symptoms in
rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis and ankylosing …

Over the last decades, advances in the knowledge of immunology have led to the
identification of immune checkpoints, reinvigorating cancer immunotherapy. Although …

During host immune response, an initial and sufficient activation is required to avoid
infection and cancer, yet an excessive activation bears the risk of autoimmune reactivity and …

Interactions of CD70, a tumor necrosis factor-related cell surface ligandand its receptor,
CD27, are thought to play an important role for T-, B-, and natural killer-cell activation …

We found that the plasma of patients with active systemic lupus erythematosus (SLE) could
induce a human B-cell line (Ramos) to express high levels of immune accessory molecules …

Objective Altered composition of the B cell compartment in the pathogenesis of systemic
lupus erythematosus (SLE) is characterized by expanded plasmablast and IgD–CD27 …

Abstract CD134 (OX40) is a member of the tumor necrosis factor (TNF) receptor (TNFR)
family that can be expressed on activated T lymphocytes. Interaction between CD134 and its …

Although normally restricted to activated T and B cells and mature dendritic cells, constitutive
expression of CD70, a member of the tumor necrosis family, has been described in both …

Objective To critically examine current evidence regarding the role of the CD27–CD70
pathway in the pathophysiology of autoimmune disease with a focus on understanding the …

The interaction between CD27 and its ligand, CD70, has been implicated in regulating
cellular immune responses to cancer. In this article, we report on the role of soluble CD27 …